Priyanthi N.P. Gnanapragasam

This study identifies nanobodies targeting conserved SARS-CoV-2 RBD epitopes that neutralize variants and zoonotic sarbecoviruses.

This paper develops a gp120-specific CD4 variant (gCD4) that improves thermostability, reduces off-target class II MHC binding, and enhances HIV-1 neutralization compared to existing CD4-Ig biologics.

This study evaluates ALD-delivered mosaic-8b RBD-nanoparticles, showing improved cross-reactive antibody responses against mismatched sarbecoviruses compared to conventional immunizations.

This study evaluates bivalent S-EABR mRNA-LNP boosters in pre-vaccinated mice, showing enhanced neutralizing responses and polyclass RBD antibody diversity against SARS-CoV-2 variants.

This paper designs and tests an HIV-1 vaccine candidate that targets three bNAb epitopes, showing it elicits combined immune responses in animal models.

This paper develops mosaic RBD-nanoparticles to induce cross-reactive anti-sarbecovirus antibodies in animals, demonstrating their effectiveness against SARS-CoV-2 variants and zoonotic viruses.

The paper identifies minimal somatic hypermutations required for CD4bs bNAb neutralization breadth and uses structural data to guide HIV-1 vaccine immunogen design.

The paper designs mosaic nanoparticles with SARS-like betacoronavirus RBDs to enhance cross-reactive immune responses in mice, finding that mosaic-7COM elicits stronger responses against zoonotic sarbecoviruses and Omicrons.

The paper shows mosaic-8b nanoparticles induce broader cross-reactive antibodies than homotypic ones, even in pre-vaccinated animals, suggesting potential for improved vaccine design against emerging sarbecoviruses.

The paper detects and characterizes the SARS-CoV-2 lineage B.1.526 in New York, showing its rapid growth and potential impact on neutralization.